Peptide register

Small-molecule NNMT inhibitor studied preclinically; no registered human trials, no approval.

Synthetic analogue of parathyroid hormone-related protein (1-34); approved prescription medicine for osteoporosis.

Prescription-only in the US, EU, UK, Switzerland, Australia and Japan; not approved in Canada; approved for men only in the US

Endogenous tetrapeptide from thymosin beta-4, a marker of ACE inhibition; tested as goralatide in the 1990s, never approved.

Early clinical development in the 1990s, not continued; not approved in any market

Synthetic analogue of the Semax peptide family; no registered human trials and no approval.

Proapoptotic peptidomimetic; early trial work stopped, no approval and no active development.

Copper complex of the tripeptide Ala-His-Lys used as a cosmetic ingredient; not approved as a medicine.

Sold as a cosmetic ingredient under a name the binding EU ingredient glossary does not carry; no expert safety assessment and no approval as a medicine

AMP-activated protein kinase activator trialled in the 1990s; not approved in any market.

Growth hormone fragment 176-191; drug development discontinued, no medicine approval.

Holds a food-ingredient status in the US, not a medicine approval

Erythropoietin-derived innate repair receptor agonist studied in phase 2; not approved anywhere.

Synthetic pentadecapeptide studied mainly in animal models; no approval anywhere.

Australia: Schedule 4

Dual GIP and GLP-1 receptor agonist in phase 3 for addiction, depression and other non-metabolic uses; not approved anywhere.

Khavinson tetrapeptide Ala-Glu-Asp-Leu, a supplement in Russia and a medicine nowhere; no registered trials, lung link shown in animals.

Registered in Russia as a dietary supplement; the Russian medicines register shows no registration

Long-acting amylin analogue in phase 3 development; not approved anywhere.

Khavinson short-peptide bioregulator (Ala-Glu-Asp-Arg); no registered human trials and no approval as a medicine.

Khavinson short-peptide bioregulator; no registered human trials and no approval as a medicine.

Peptide preparation from porcine brain tissue; prescription medicine in some countries, not approved in the US or EU.

Not approved in the US; national approvals only

Khavinson bioregulator (Glu-Asp-Gly); its developers list it as a stomach and stress peptide, not a lung one; no trials, no approval.

Growth-hormone-releasing hormone analogue without a drug affinity complex; not approved anywhere.

Long-acting growth-hormone-releasing hormone analogue; no approval in any market.

Khavinson short-peptide bioregulator; no registered human trials and no approval as a medicine.

Khavinson short-peptide bioregulator (Glu-Asp-Pro); no registered human trials and no approval as a medicine.

Nonapeptide first described in the 1970s; no marketing authorisation in any market.

Angiotensin IV-derived peptidomimetic; never given to a person in a trial, and its key mechanism paper was retracted.

Long-acting GLP-1 receptor agonist fusion protein; approved prescription medicine.

Selective amylin receptor agonist in phase 3 development for obesity; not approved in any market.

Dual GIP and GLP-1 receptor agonist in phase 3 development for obesity and type 2 diabetes; not approved in any market.

Synthetic tetrapeptide from the Khavinson bioregulator series; no approval in any market.

First licensed GLP-1 receptor agonist; approved prescription medicine since 2005.

Originator products discontinued in the US

Recombinant follistatin isoform sold for laboratory use; the only human data come from gene therapy, not the protein.

D-retro-inverso peptide studied in rodent senescence models; no approval in any market.

Copper-free human tripeptide, a cosmetic ingredient approved nowhere as a medicine; all human studies used the copper complex GHK-Cu.

Listed as a cosmetic ingredient in the EU; no approval as a medicine

Copper-binding tripeptide used as a cosmetic ingredient; not approved as an injectable medicine.

No approval as an injectable medicine

Growth-hormone-releasing peptide; single-dose studies in the 1990s, one registered trial abandoned in 2007, no approval anywhere.

Growth-hormone-releasing peptide; licensed in Japan as a diagnostic agent only.

Japan only, diagnostic use

Growth-hormone-releasing peptide; no approval as a medicine in any market.

Endogenous tripeptide antioxidant sold as an oral supplement; injectable forms are unapproved.

Injectable forms hold no marketing authorisation

Gonadotrophin-releasing hormone; approved prescription medicine in several European markets.

EU approvals only; US products discontinued

Growth-hormone-releasing peptide studied in the 1990s; no approval in any market.

Recombinant human growth hormone; prescription-only in every market listed, and 191AA is a grey-market label.

Glycoprotein hormone; approved prescription medicine used in fertility and endocrine care.

Gonadotrophin preparation containing FSH and LH activity; approved prescription medicine.

24-amino-acid peptide encoded in mitochondrial DNA; studied preclinically, not approved in any market.

Modified insulin-like growth factor 1 analogue sold for laboratory use; never tested in a clinical trial.

Selective ghrelin receptor agonist; development discontinued, not approved in any market.

Decapeptide fragment of kisspeptin studied in reproductive medicine trials; not approved anywhere.

Tripeptide fragment of alpha-melanocyte-stimulating hormone; preclinical only, no approval.

Amino acid derivative sold as a supplement; a prescription form exists for carnitine deficiency.

A prescription levocarnitine medicine exists for carnitine deficiency

GLP-1 receptor agonist; approved prescription medicine since 2009.

Khavinson short-peptide bioregulator (Lys-Glu-Asp-Ala); no registered trials, no approval, the only human account is in a patent.

Human cathelicidin antimicrobial peptide studied in phase 2 wound trials; not approved anywhere.

Synthetic lipopeptide (palmitoyl pentapeptide-4) listed as a cosmetic ingredient in the EU; not approved as a medicine.

No approval as a medicine; listed as a cosmetic ingredient only

Dual glucagon and GLP-1 receptor agonist; approved as a prescription medicine in China in 2025.

China only

Splice variant of insulin-like growth factor 1; the peptide sold under this name has never been given to a person.

Melanocortin-1 receptor agonist; approved prescription medicine in the US and the EU.

Approved for a rare photodermatosis only

Non-selective melanocortin receptor agonist; never submitted for approval in any market.

Pineal hormone: prescription-only in the EU, UK, Switzerland and Canada, a supplement without FDA approval in the US, injectable nowhere.

Status differs by country and form: a prescription medicine in the EU, UK, Switzerland and Canada, a dietary supplement without FDA approval in the US; injectable forms hold no marketing authorisation anywhere

Mitochondrial-derived 16-amino-acid peptide; one interventional human trial registered, no approval.

Acetylated and amidated Epitalon variant sold by vendors; no studies of its own, found in no database, and no approval.

This variant appears in no database, has no studies and no registration; the parent peptide epitalon is not a medicine anywhere

Acetylated and amidated Selank variant sold by vendors; no studies of its own, one analytical paper, no PubChem entry, no approval.

The parent peptide Selank is registered as a medicine in Russia only; this modified form is not, as the registration covers only the exact sequence. The manufacturer confirmed non-prescription supply in 2017

Acetylated and amidated Semax variant sold by vendors; no studies of its own, only one analytical paper, and no approval.

The unmodified parent peptide is registered as a medicine in Russia; this variant is not, as the registration covers only the exact Semax sequence

Coenzyme sold as an oral supplement; an injectable form is approved only in China.

Injectable form approved only in China (prescription); unauthorised elsewhere

Khavinson short-peptide bioregulator (Glu-Asp-Leu); all reviewed work concerns the kidney, and there are no registered trials.

Posterior pituitary peptide hormone; long-established approved prescription medicine.

Ciliary neurotrophic factor-derived peptide studied in rodents; not the cell-cycle protein of the same name, never tested in people.

Khavinson short-peptide bioregulator (Lys-Glu-Asp-Trp); no registered human trials and no approval as a medicine.

Spadin-derived TREK-1 channel blocker peptide; preclinical only, no approval anywhere.

Pegylated form of a mechano growth factor peptide; no published study and no confirmed chemical identity.

Khavinson short-peptide bioregulator; no registered human trials and no approval as a medicine.

p53-derived peptide studied in cell and animal models only; never in a clinical trial, and the subject of an FDA safety warning.

Khavinson short-peptide bioregulator (Lys-Glu-Asp-Pro); no registered trials, no approval, and the subject of an FDA warning letter.

Melanocortin receptor agonist; prescription medicine approved in the United States in 2019, with no approval in any other market.

US only; also dispensed in China's Hainan free trade port without NMPA registration

Cell-penetrating peptide blocking the CXXC5-Dishevelled interaction; preclinical only, not approved anywhere.

Triple GIP, GLP-1 and glucagon receptor agonist in phase 3; not approved anywhere.

Synthetic tuftsin analogue peptide; registered as a prescription medicine in Russia.

Russia only

GLP-1 receptor agonist; approved prescription medicine in the US and the EU.

Synthetic ACTH (4-10) fragment analogue; registered as a prescription medicine in Russia.

Russia only

GHRH fragment; former US prescription medicine (withdrawn 2009, not for safety), today compounded on prescription only.

Former US prescription medicine, withdrawn 2009 for non-safety reasons; today only compounded on prescription; named in the German prescription-only schedule

Small-molecule estrogen-related receptor agonist; preclinical only, no approval anywhere.

Acetylated octapeptide from the human SNAP-25 protein, sold as a cosmetic ingredient; not a medicine and not a copper peptide.

Cardiolipin-binding tetrapeptide; FDA-approved prescription medicine for Barth syndrome since 2025.

US only (Barth syndrome)

Dual glucagon and GLP-1 receptor agonist in phase 3 development; not approved in any market.

Full-length thymosin beta-4: 43 amino acids; studied in clinical trials, distinct from the TB-500 fragment.

Acetylated seven-amino-acid fragment of thymosin beta-4 (Ac-LKKTETQ); distinct from full-length TB-4.

Non-acetylated thymosin beta-4 fragment (17-23), INN fequesetide; TB-500 is the acetylated form. Approved nowhere.

Recombinant parathyroid hormone fragment (1-34); approved prescription medicine for osteoporosis.

Growth-hormone-releasing hormone analogue; approved prescription medicine for one indication.

Khavinson bioregulator (Lys-Glu-Asp-Gly); sold as a testis peptide, but all peer-reviewed animal work concerns the pituitary and thyroid.

Polypeptide complex extracted from calf thymus, not a defined molecule; prescription medicine in Russia, not approved in any western market.

Approved in Russia only (Rx since 1982, re-registered 2024); FDA warning letter 2024 over US sales

Synthetic dipeptide (Glu-Trp), also known as oglufanide; a registered medicine in Russia only, not approved in the EU or US.

Registered in Russia only, where the injection is prescription-only; no approval in the EU or US, and Western development was discontinued after a negative phase 3 trial

Fully synthetic 28-amino-acid peptide identical to a natural thymic peptide; prescription-only medicine in Italy and China.

Approved only in Italy and China; not approved in the US, the EU centrally, the UK, Canada, Switzerland, Japan or Australia

Zinc-dependent thymic nonapeptide hormone described in the 1970s; not approved as a medicine anywhere.

Studied in small clinical series in the 1980s; no marketing authorisation and no active development

Dual GIP and GLP-1 receptor agonist; approved prescription medicine.

Gonadotrophin-releasing hormone agonist; prescription-only medicine, licensed among other uses for endometriosis and precocious puberty.

Synthetic Khavinson tripeptide (Lys-Glu-Asp); a food supplement in Russia, no medicine approval, and not the bovine vessel preparation.

Khavinson dipeptide (Lys-Glu); submitted for medicine registration in Russia but never approved; on the market only as a food supplement.

Vasoactive intestinal peptide; aviptadil is a prescription medicine in several European markets, but only as a fixed combination.

Prescription-only and approved solely as a fixed combination with phentolamine, in Germany, Denmark, Finland, France, Norway, Sweden and the UK

Cyanocobalamin, a synthetic form of vitamin B12 and not a peptide; listed because it is mixed into compounded weight-loss injections.

Varies by country and form: injections are prescription-only in the US, Switzerland and the UK, pharmacy-only without prescription in Germany; oral forms are sold as supplements

Dual GLP-1 and GIP receptor agonist in phase 3 as a weekly injection, also tested as a daily tablet; not approved in any market.